PainReform announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, non-opiate, post-surgical pain relief. The Company conducted comprehensive in vitro studies to assess the impact of PRF-110 on both non-absorbable and resorbable sutures. Given that suture materials are often in proximity to the PRF-110 oily solution following surgery, it was critical to evaluate whether PRF-110 would affect the mechanical properties of these sutures. The mechanical integrity, including breaking force and elongation, of PROLENE non-absorbable sutures and Vicryl resorbable sutures was tested at the outset and after 14 days, with comparisons made to a control group. The results indicated that PRF-110 does not impact the mechanical properties of either PROLENE or Vicryl sutures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRFX:
- PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
- PainReform exercises warrants for $1.58M in gross proceeds
- PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
- Upcoming Stock Splits This Week (September 9 to September 13) – Stay Invested
- PainReform Ltd trading halted, news pending